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ABSTRACT
Introduction: Skin and skin structure infections are an increasing cause of hospitalization. Although mortality is relatively low, skin and 
skin structure infections are associated with prolonged hospital length of stay and high costs. Oxazolidinones have been suggested as 
a tool to treat infected patients in the ambulatory setting in order to decrease hospital length of stay. We wanted to address the evidence 
associated with the use of oxazolidinones in the treatment of skin and skin structure infections.
Material and Methods: In this observational retrospective study we analyzed the anonymized diagnosis related group coded informa-
tion from the Portuguese database for hospital admissions, that included all adult patients with a diagnosis of oxazolidinone use and a 
SSSI, discharged between 2010 and 2015.
Results: During the study period, a total of 5518 patients had a diagnosis of oxazolidinone treatment. We selected 483 of those who 
were also diagnosed with a skin and skin structure infections. Their mean age was 64.9 years and 62.7% were male. The median hos-
pital length of stay was 27 days (Inter quartile range 13 – 56) and the mortality rate was 12.6%. The prevalence of secondary anemia 
and of thrombocytopenia in the whole group treated with oxazolidinones was 2.5% and 3%, respectively.
Discussion: Despite the high bioavailability of oxazolidinones, we were not able to find evidence that its use was associated with a 
decrease of mortality or hospital length of stay (due to early discharge) of patients with skin and skin structure infections. 
Conclusion: In this study we were not able to find evidence that oxazolidinones had any clinically significant benefit. A structured 
approach, including antibiotics with favorable pharmacokinetic and safety profile as well as a carefully planned ambulatory follow up 
may be needed.
Keywords: Hospitalization; Oxazolidinones; Skin Diseases, Bacterial/drug therapy; Soft Tissue Infections/drug therapy
RESUMO
Introdução: As infeções da pele e das estruturas da pele são uma causa crescente de hospitalização. Apesar da baixa mortalidade, 
as infeções da pele e das estruturas da pele estão associadas a internamentos prolongados e a custos elevados. O uso de oxazolidi-
nonas foi proposto como estratégia para o tratamento ambulatório destes doentes como forma de reduzir a duração do internamento. 
Pretendeu-se avaliar a evidência associada ao uso de oxazolidinonas no tratamento de infeções da pele e das estruturas da pele.
Material e Métodos: Neste estudo retrospectivo observacional analisámos a base de dados portuguesa anonimizada, codificada por 
grupos de diagnóstico homogéneos. Incluímos adultos com alta hospitalar entre 2010 a 2015 com diagnóstico de alta de utilização 
de oxazolidinonas. Nesse grupo selecionamos os que apresentavam diagnóstico concomitante de infeções da pele e das estruturas 
da pele.
Resultados: Durante o período em estudo 5518 doentes receberam o diagnóstico de tratamento com oxazolidinona. Destes selecio-
námos 483 com diagnóstico concomitante de infeções da pele e das estruturas da pele. Destes, 62,7% eram homens e a idade média 
foi de 64,9 anos. A duração mediana do internamento hospitalar foi de 27 dias (intervalo interquartil 13 – 56) e a taxa de mortalidade 
foi 12,6%. A prevalência de anemia secundária, nos 5518 doentes tratados com oxazolidinonas, foi de 2,5% e a de trombocitopénia 
foi de 3%.
Discussão: Apesar da elevada biodisponibilidade das oxazolidinonas, neste estudo não conseguimos identificar evidência que o seu 
uso estivesse associado a diminuição da mortalidade ou da demora média hospitalar (relacionado com alta precoce) dos doentes com 
infeções da pele e das estruturas da pele. 
Conclusão: Neste estudo não encontramos evidência de que a utilização de oxazolidinonas esteja associada a benefícios clínicos 
significativos. Estratégias integradas, incluindo antibióticos com bom perfil de segurança e de farmacocinética, bem como planeamen-
to adequado para seguimento em ambulatório parecem ser necessários. 
Palavras-chave: Doenças Bacterianas da Pele/tratamento; Hospitalização; Infecções dos Tecidos Moles/tratamento; Oxazolidinonas
INTRODUCTION
Skin and skin structure infections (SSSI) are among the 
most frequent human bacterial infections. Skin and skin 
structures infections typically involve deep soft tissue and 
represent an increasingly significant cause of hospitaliza-
tion.1–3 Moreover, these infections often occur in patients 
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with significant comorbidities and frailty and are associated 
with substantial health costs,4,5 prolonged hospital length 
of stay (LOS) and frequently require complex nursing care 
or even a surgical intervention.4–6 Diabetes seems to be an 
important risk factor and may increase the incidence as 
much as 50%.3
Compliance with international guidelines is poor and 
patients are often managed according to local practices.7 
This reinforces the need for hard patient centered evidence 
in this field.
Even in patients admitted to Intensive Care Units, SSSI 
may represent a substantial burden, representing as much 
as 5% – 6%8,9 of the total number of infections, and seem to 
be more common during Spring and Summer.9
Most SSSI are caused by Gram positive bacteria, espe-
cially Staphylococcus aureus and β-haemolytic Streptococ-
ci.3,10 The prevalence of Staphylococcus aureus seems to 
be increasing and has become the single most reported 
pathogen.1,11
Usually, SSSI are treated with antibiotics and surgi-
cal drainage, as appropriate. However, the emergence of 
strains resistant to multiple agents has complicated anti-
biotic choices.4,10 Overall, the most problematic SSSI are 
caused by methicillin-resistant Staphylococcus aureus 
(MRSA).1 Both community-acquired (CA) and hospital-ac-
quired (HA) MRSA have become predominant pathogens 
in nosocomial SSSI, making these infections increasingly 
challenging to treat.11,12
The requirement of hospitalization for these patients is 
mostly related to the need of surgical debridement, nursing 
care and intravenous antibiotics. Outpatient parenteral antibi-
otic treatment (OPAT) has been suggested as an appropriate 
and safe alternative, with lower costs and improved patient 
satisfaction.13 More recently, the development of oral antibi-
otic drugs with high bioavailability, that are effective against 
MRSA, has created another cheaper alternative to OPAT.14,15
Moreover, antibiotics with high oral bioavailability may 
be given to patients already admitted to the hospital, in 
order to facilitate an earlier discharge. Oxazolidinones rank 
high on this approach to treat SSSI, although some studies 
failed to show a benefit of these drugs in the reduction of 
hospital LOS.16 The need for complex nursing care, fear of 
drug toxicity, especially hematological toxicity and doubts 
about antibiotic compliance in the ambulatory setting may 
preclude this strategy.
The aim of this study was to evaluate if the use of oxaz-
olidinones was associated with improved clinical outcomes 
in patients with SSSI, namely lower mortality and lower hos-
pital LOS, when compared with previously published data.
MATERIAL AND METHODS
The Central Administration of the Health System of the 
Portuguese Ministry of Health contains administrative and 
clinical data of all admissions to hospitals from the national 
health service which covers the whole population of main-
land Portugal. This information, including diagnoses and 
procedures, is diagnosis related group (DRG) encoded. 
DRG coding is performed by trained physicians and based 
on hospital discharge reports, according to the International 
Classification of Diseases, 9th Revision Clinical Modification 
(ICD-9-CM). DRG codings are periodically audited. 
In this study, we retrospectively analyzed all hospital 
admissions of adults with a report of oxazolidinone use 
(ICD-9-CM 00.14), who were discharged between 2010 and 
2015. Patients under 18 years of age were excluded.
We focused our analysis on the use of oxazolidinone 
to treat a SSSI. We screened the first 10 diagnoses of all 
the included patients and segregated patients with a diag-
nosis of a SSSI, namely erysipela (ICD-9-CM 035), cellu-
litis or abscess of hand or fingers (681.xx), other cellulitis 
or abscesses (682.xx), other local SSSI (686.xx), impetigus 
(684), folliculitis (704.09), diabetic foot infection (249.80, 
250.81, 250.80), sore pressure ulcer (707), other post 
traumatic wound infection (958.3), post surgical infection 
(998.5x e 998.83), human or animal byte (E906.5) or gan-
grene (785.4).
To focus our study only on the use of an oxazolidinone 
to treat SSSI, we excluded from further analysis patients 
who also had a diagnosis of another infection at any other 
focus site, especially endocarditis, osteomyelitis, pneumo-
nia, burns and necrotizing fasciitis.
Finally, we checked the selected records for the pres-
ence of comorbidities, especially diabetes (ICD-9-CM 250). 
In order to address the incidence of toxicity, especially 
hematological toxicity, we evaluated all the population with a 
diagnosis comprising oxazolidinone use for the presence of 
secondary thrombocytopenia (ICD-9-CM 287.4 and 287.5) 
or anemia (ICD-9-CM 284.xx). We also calculated the mor-
tality rate of patients presenting any of these diagnoses. 
The study was submitted to the Central Administration of 
the Health System of the Portuguese Ministry of Health who 
approved the protocol and provided the requested data. 
The analysis of clinical information preserved total 
patient anonymity and only anonymized data was analyz-
ed. No database with patients’ identification was created. 
Therefore informed consent was waived. Descriptive statis-
tics were performed, namely absolute (n) and relative fre-
quencies (%) for qualitative variables and mean ± standard 
deviation (SD) for quantitative variables. Statistical analy-
ses were carried out using STATA®, Version 15, statistical 
software system.
This study was performed in accordance with the Hel-
sinki Declaration for Human Research. 
RESULTS
A total of 5518 patients were discharged from the hos-
pital with a diagnosis of  oxazolidinone use during the study 
period. We checked the first 10 discharge diagnoses from all 
patients and segregated those with a diagnosis of a SSSI. 
We excluded patients with an infection at any other site, 
regardless of concomitant SSSI. Overall, 483 patients with 
a discharge diagnosis of one or more SSSI were selected.
Mean age was 64.9 [standard deviation (SD) 15.1], 
including 56.1% older than 65 years and 29% older than 
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Hospital LOS was very long, with a median of 27 days 
[Inter quartile range (IQR) 13 – 56] and an even high-
er mean value of 45.4 days (SD 56.9), related with some 
patients having a very prolonged hospital stay. These fig-
ures remained similar even after excluding patients who 
died (median 24 days [IQR 13 – 46]; mean 43.1 days 
(SD 55.2)). Mortality rate was also very high (12.6%), even 
though only 7 patients were admitted to an Intensive Care 
Unit (Table 3).
In the whole population (5518 patients with a diagnosis 
of oxazolidinone use), the prevalence of secondary anemia 
was 2.5%; thrombocytopenia was diagnosed in 3% of this 
population. These two groups had both a significantly higher 
mortality rate (chi-square test: 33.6% vs 45.7%, p = 0.003; 
and 33.6% vs 43.4%, p = 0.009, respectively).
DISCUSSION
In this study we address the clinical use of oxazolidinones 
to treat SSSI in patients admitted to the hospital. We found 
that this group had a high mortality rate, 12.6%, and also 
a very long hospital LOS (median 27 [IQR 13 – 56] days). 
Consequently, we were not able to find any evident benefit 
regarding the use of these drugs in this hospital population.
We believe that the high mortality and prolonged hos-
pital LOS are mostly related with comorbidities and not 
necessarily with the infection itself. Figtree et al17 found 
that the presence of bacteremia or low albumin levels (that 
can be seen as a marker of frailty and chronic inflamma-
tion) were independent predictors of mortality in SSSI. 
Table 1 – Skin and soft tissue infections of patients treated with 
oxazolidinones
Erysipela (ICD-9-CM 035) 48 (3.7%)
Cellulitis or abscess of hand or fingers
(ICD-9-CM 681.XX) 24 (1.8%)
Other cellulitis or abscesses (ICD-9-CM 682.xx) 348 (26.7%)
Other local acute bacterial skin and skin 
structures infection (ICD-9-CM 686.xx) 23 (1.8%)
Impetigus (ICD-9-CM 684) 0
Folliculitis (ICD-9-CM 704.09) 0
Diabetic foot infection
(ICD-9-CM 249.80, 250.81, 250.80) 1 (0.1%)
Sore pressure ulcer (ICD-9-CM 707) 379 (29.1%)
Other post traumatic wound infection
(ICD-9-CM 958.3) 4 (0.3%)
Post-surgical infection
(ICD-9-CM 998.5x + 998.83) 388 (29.8%)
Human or animal byte (ICD-9-CM E906.5) 0
Gangrene (ICD-9-CM 785.4) 88 (6.8%)
Discharge diagnosis (n = 1303) of patients who received oxazolid-
inones during hospital stay with a skin or skin structure infection. 
A single patient could have more than one skin and skin structures 
infection. Patients with other infection focus were excluded from 
analysis and are not represented in the table.
Table 2 – Concomitant comorbidities of patients with skin and soft 
tissue infections
Cerebrovascular disease
(ICD-9-CM 430.XX – 438.XX) 9 (1.9%)
Dementia (ICD-9-CM 290.XX) 9 (1.9%)
Chronic cardiac failure (ICD-9-CM 428.XX) 46 (9.5%)
COPD and respiratory failure
(ICD-9-CM 491.XX + 492.XX+518.8X) 1 (0.2%)
Chronic renal failure
(ICD-9-CM 585.XX-586.XX) 86 (17.8%)
Chronic hepatic failure
(ICD-9-CM 571.XX+572.8) 9 (1.9%)
Atherosclerosis (ICD-9-CM 440.XX) 50 (10.4%)
Diabetes mellitus (ICD-9-CM 250.XX) 248 (51.3%)
Neoplasic disease (ICD-9-CM 140.XX-208.XX) 27 (5.6%)
Number of patients treated with oxazolidinones for a skin and skin 
structure infection who also presented a discharge diagnosis of sig-
nificant comorbidities. Only 156 patients (32.3%) did not have at 
least one of these diseases.
75 years. Only 30 patients were younger than 40 years. 
Male sex was predominant (62.7% of this patients group).
Cellulitis and abscess (77%), pressure sore ulcer infec-
tion (78.5%) and post-surgical infections (80.3%) were all 
very commonly diagnosed (Table 1). Even though diabetes 
was a common comorbidity, being diagnosed in 27.7% of 
patients, only 1 patient presented a diabetic foot infection.
Comorbidities were common, especially diabetes 
(Table 2). Its prevalence increased with age, being present 
in more than 70% of patients aged over 60 years (Fig. 1). 
Older age was common but 10% of patients were younger 
than 50 years.
Figure 1 – Distribution of patients according to age and the pres-
ence of comorbidities
140
120
100
80
60
40
20
0
< 40 40–49 50–59 60–69 70–79 ≥80
ComorbiditiesNo comorbidities
Table 3 – Clinical outcomes
Clinical outcomes Study population (n = 483)
Mortality, n (%) 61 (12.6%)
Length of hospital stay, days, 
median [Interquartile range]
27 [13 – 56]
Admission to ICU, n (%) 7 (1.4%)
ICU: intensive care unit
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Furthermore, age over 60 years, infection with MRSA, 
symptoms duration of more than four days before hospi-
tal admission, were also associated with a hospital LOS 
longer than seven days. This old age and high prevalence 
of comorbidities, that we identified in our population (Fig. 1), 
were also found in other studies.9,18 In fact, the increasing 
number of patients with multiple comorbidities (especially 
diabetes) that are admitted with an infection represent a 
significant burden for the health system, not only due to the 
required prolonged hospitalization, but also because it may 
be challenging to treat these patients appropriately. This 
population has a frequent exposure to health care facilities 
and antibiotics, which can lead to an increase in the num-
ber of resistant microorganisms and, therefore, to a higher 
risk of therapeutic failure, infection recurrence and death.9 
In an international, multicenter, observational, retrospective 
study, including 1995 patients with a SSSI,19 comorbidities 
were present in 78% (diabetes in 34%) and infection recur-
rence was noted in 26%. Nevertheless, the mortality rate 
was only 3.4% and hospital LOS 18.5 [12],19 figures were 
lower compared to our population.
Usually, selection of the antibiotic treatment for SSSI 
is based on the clinical presentation, host comorbidities, 
medical history and infection focus.10,20 However, the rise 
of resistant pathogens (especially MRSA), even in patients 
without known risk factors,21 has increased the importance 
of diagnostic microbiology and antibiotic susceptibility test-
ing. Such actions can promote appropriate antibiotic pre-
scribing and stewardship.22
Some studies have reported high rates of MRSA in SSSI 
or similar infections, both CA-MRSA and HA-MRSA, rang-
ing from 22.4% to 74.8%,1,12 but with important geographic 
variations.23 In Portugal CA-MRSA has already been report-
ed,24 but HA-MRSA clearly predominates.
Our Portuguese group of patients presented a very high 
mortality rate, 12.6%, which is much higher than in other 
published studies (ranging from 0.4% to 5.2%).18 We believe 
that this difference may be due to selection bias, as a con-
sequence of the criteria that were used. Only patients that 
received a diagnosis of an oxazolidinone use were included 
in this group. These antibiotics were commonly used as a 
rescue therapy, in patients with severe disease, who had 
already failed other lines of therapy, especially vancomycin. 
Taking into account the specificities of the Portuguese DRG 
Hospital Funding Model, physicians are more likely to code 
‘oxazolidinone use’ when this antibiotic is used as an excep-
tion, namely in rescue therapy. In fact, no patient with less 
severe disease, either impetigus or folliculitis was included 
in this series (Table 1).
These patients, who fail their first line of therapy, usually 
have more comorbidities, more severe infections including 
organ failure, often have frailty associated with immunose-
nescence,26 and have an increased risk of dying.
Positive impact from the use of oxazolidinones, as 
first therapy to treat SSSI, is noted in some metanalysis,27 
including the 2016 revised Cochrane review.28 Furthermore, 
this benefit seems to be mostly related to ‘clinical cure’ but 
with no clear impact in mortality. Furthermore, conflicting 
clinical results are commonly reported , and studies report-
ing benefits are often industry funded.28
One of the main interests in the use of oxazolidinones 
for SSSI is the possibility of their use as outpatient oral ther-
apy. These drugs have an excellent oral bioavailability and 
maintain their large spectrum of activity, even when given 
by oral route in the ambulatory setting.30 However, fear 
of adverse events,31 especially hematological toxicity32 in 
patients undergoing prolonged antibiotic courses, may pre-
clude this strategy. In our whole patient population, that was 
exposed to oxazolidinones during the hospital stay, regard-
less of the focus of infection, thrombocytopenia and anemia 
were reported at discharge in relatively small numbers, 3% 
and 2.5%. However, patients who also had this hematolog-
ical diagnosis had a significantly higher mortality rate. Fear 
of this complication in patients discharged while receiving 
oral treatment with oxazolidinones may partly explain the 
long hospital LOS that we documented in SSSI. Compli-
ance with oral treatment may also be lower than ideal and 
patients commonly overstate their medication adherence.33 
This lack of compliance may increase therapeutic failure.33
Moreover, patients with comorbidities may be at an 
increased risk of low compliance with antibiotic therapy in 
the ambulatory setting. This, along with the need for com-
plex nursing (and even surgical) care, may preclude a plan 
for an early discharge. Finally, we believe that some of 
these patients died with an infection rather than died from 
an infection. In fact, this low rate of admission to an inten-
sive care unit (only seven patients) seems to be related to 
a low perspective of recovery. A multidisciplinary approach, 
including plans for good palliative and nursing care at home 
may help improve patients’ quality of life and to reduce hos-
pital dependence and costs.
To facilitate the promotion of this ambulatory care, the 
use of antibiotics with a favorable pharmacokinetics (espe-
cially very long half-life) and safety profile, that maintain 
activity against the most common pathogens (including 
MRSA), facilitate patient adherence and are an important 
alternative to these patients, and thus facilitating early dis-
charge and even cost control, could be an interesting com-
plementary approach.
We acknowledge that this study has several limitations. 
First, we did not include a control group and could directly 
not compare hospital mortality or LOS; second, no micro-
biological documentation was studied; third, the number 
of patients included was low, probably due to underreport-
ing; fourth, the study was retrospective, and this may have 
caused some unknown bias; finally, the diagnosis of ‘oxa-
zolidinone use’ did not allow to discriminate patients who 
received this antibiotic early during their hospital stay from 
those who received it later, as rescue therapy. Furthermore, 
we do not know the total duration of the oxazolidinone 
treatment and that may be relevant, not only to evaluate 
efficacy but also to interpret our toxicity data. In fact, Sori-
ano et al32 clearly show a significant increase in both ane-
mia and thrombocytopenia after 10 days of exposure.
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CONCLUSION
We believe that these findings provide a good perspec-
tive on the use of oxazolidinones in the therapeutic man-
agement of patients with SSSI. Unlike what has previously 
been suggested, this population, despite receiving oxazo-
lidinones to treat SSSI, had prolonged hospital LOS and a 
high mortality rate. We think that this should be reassessed 
in further studies (either prospective or retrospective), 
focusing in patient details and assessing patient centered 
outcomes, i.e. not only hospital mortality but also hospital 
LOS and quality of life.
We believe that the improvement of the outcomes of this 
population relies mainly on a structured approach, including 
these drugs and others with a favorable pharmacokinetic 
and safety profile. Finally, a multidisciplinary plan, includ-
ing not only clinical but also palliative care, is necessary to 
address this growing population in the ambulatory setting.
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